Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Invasive Bladder Cancer × Radiotherapy × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 100 Lung Neoplasms 77 Lymphoma 73 Head and Neck Neoplasms 71 Glioblastoma 69 Breast Neoplasms 65 Rectal Neoplasms 63 Squamous Cell Carcinoma of Head and Neck 61 Esophageal Neoplasms 56 Prostatic Neoplasms 54 Leukemia 50 Central Nervous System Neoplasms 49 Pancreatic Neoplasms 47 Precursor Cell Lymphoblastic Leukemia-Lymphoma 43 Lymphoma, Non-Hodgkin 41 Hodgkin Disease 41 Lymphoma, Large B-Cell, Diffuse 39 Lymphoma, Follicular 38 Leukemia, Lymphocytic, Chronic, B-Cell 37 Colorectal Neoplasms 37 Esophageal Squamous Cell Carcinoma 36 Brain Neoplasms 36 Burkitt Lymphoma 35 Gliosarcoma 33 Lymphoma, Large-Cell, Immunoblastic 31 Adenocarcinoma Of Esophagus 31 Lymphoma, Mantle-Cell 28 Lymphoma, B-Cell, Marginal Zone 28 Neoplasms 25 Uterine Cervical Neoplasms 24

Interventions

tremelimumab 1 durvalumab 1 Radiotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03702179 2024-12-05

IMMUNOPRESERVE

Spanish Oncology Genito-Urinary Group

Phase 2 Completed

32 enrolled 19 charts

Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡